{"schema_version":"secwatch.filing_event.v1","accession":"0000882095-23-000003","form_type":"8-K","ticker":"GILD","cik":"0000882095","company_name":"GILEAD SCIENCES, INC.","filed_at":"2023-02-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:48.371716+00:00","generated_at":"2026-06-20T03:08:37.901439+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Gilead Q4 2022 rev $7.4B, EPS $1.30; ex-Veklury sales +9%; FY 2023 guidance $26.0-26.5B product sales","bullets":["Q4 revenue $7.4B (+2%); product sales ex-Veklury +9% to $6.3B.","GAAP diluted EPS Q4 $1.30 vs $0.30; non-GAAP $1.67 vs $0.69.","FY 2022 Biktarvy sales $10.4B (+20%); Trodelvy $680M (+79%); Cell Therapy $1.5B (+68%).","FY 2023 guidance: product sales $26.0-26.5B; GAAP EPS $5.30-5.70; non-GAAP EPS $6.60-7.00.","Q4 operating cash flow $2.6B; dividends $916M; share repurchases $791M."],"urls":{"canonical":"https://secwatch.observer/filing/0000882095-23-000003","json":"https://secwatch.observer/filing/0000882095-23-000003.json","markdown":"https://secwatch.observer/filing/0000882095-23-000003.md","text":"https://secwatch.observer/filing/0000882095-23-000003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882095/000088209523000003/0000882095-23-000003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882095/000088209523000003/gild-20230202.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T03:08:37.901439+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"979c3ee3101d6b19dee71e3d110a20f9a2e78489","claim":"GILEAD SCIENCES, INC. reported financial results for the quarter and year ended December 31, 2022.","evidence_excerpt":"On February 2, 2023 , Gilead Sciences, Inc., a Delaware corporation (“Gilead”), issued a press release announcing its financial results for the quarter and year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/882095/000088209523000003/0000882095-23-000003-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter and year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}